BR9510490A - Combined two-component system designed for use in a mustard ribonucleotide host pharmaceutical composition half component mutant enzyme process to control neoplastic cell growth in a plasmid host vector and cell polynucleotide sequence - Google Patents

Combined two-component system designed for use in a mustard ribonucleotide host pharmaceutical composition half component mutant enzyme process to control neoplastic cell growth in a plasmid host vector and cell polynucleotide sequence

Info

Publication number
BR9510490A
BR9510490A BR9510490A BR9510490A BR9510490A BR 9510490 A BR9510490 A BR 9510490A BR 9510490 A BR9510490 A BR 9510490A BR 9510490 A BR9510490 A BR 9510490A BR 9510490 A BR9510490 A BR 9510490A
Authority
BR
Brazil
Prior art keywords
host
component
enzyme
prodrug
natural
Prior art date
Application number
BR9510490A
Other languages
Portuguese (pt)
Other versions
BR9510490B1 (en
Inventor
Christopher John Taylerson
Hendrikus Johannes Eggelte
Antonio Tarragona-Fiol
Brian Robert Rabin
Francis Thomas Boyle
John Frederick Hennam
David Charles Blakey
Peter Robert Marsham
David William Heaton
David Huw Davies
Anthony Michael Slater
Laurent Francois And Hennequin
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306259&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9510490(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9426192.2A external-priority patent/GB9426192D0/en
Priority claimed from GBGB9516810.0A external-priority patent/GB9516810D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of BR9510490A publication Critical patent/BR9510490A/en
Publication of BR9510490B1 publication Critical patent/BR9510490B1/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • External Artificial Organs (AREA)
  • Mechanical Coupling Of Light Guides (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Developing Agents For Electrophotography (AREA)

Abstract

PCT No. PCT/GB95/02991 Sec. 371 Date Jun. 23, 1997 Sec. 102(e) Date Jun. 23, 1997 PCT Filed Dec. 21, 1995 PCT Pub. No. WO96/20011 PCT Pub. Date Jul. 4, 1996A two component system for therapeutic treatment of a host, having a first component comprising a targeting moiety capable of binding with a tumour associated antigen, linked to a mutated enzyme capable of converting a prodrug into an antineoplastic drug, and a second component comprising a prodrug convertible under the influence of the mutated enzyme to the antineoplastic drug. The mutated enzyme is a mutated form of a natural host enzyme which recognizes its natural substrate by an ion pair interaction with the substrate, wherein the mutated enzyme and prodrug have structures such that the polarity of the mutated enzyme/prodrug ion pair interaction is reversed relative to the natural host enzyme/natural substrate ion pair interaction. The first component is substantially non-immunogenic in the host and the prodrug second component is not significantly convertible into antineoplastic drug in the host by natural unmutated host enzyme.
BRPI9510490-9A 1994-12-23 1995-12-21 structured two-component combined pharmaceutical composition for use in a host. BR9510490B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9426192.2A GB9426192D0 (en) 1994-12-23 1994-12-23 Chemical compounds
GBGB9516810.0A GB9516810D0 (en) 1995-08-16 1995-08-16 Chemical compounds
PCT/GB1995/002991 WO1996020011A1 (en) 1994-12-23 1995-12-21 Chemical compounds

Publications (2)

Publication Number Publication Date
BR9510490A true BR9510490A (en) 1998-01-13
BR9510490B1 BR9510490B1 (en) 2010-10-05

Family

ID=26306259

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9510490-9A BR9510490B1 (en) 1994-12-23 1995-12-21 structured two-component combined pharmaceutical composition for use in a host.

Country Status (23)

Country Link
US (1) US5985281A (en)
EP (1) EP0806964B1 (en)
JP (1) JP3805365B2 (en)
KR (1) KR100270650B1 (en)
CN (1) CN1095677C (en)
AT (1) ATE222124T1 (en)
AU (1) AU701916B2 (en)
BR (1) BR9510490B1 (en)
CA (1) CA2205091A1 (en)
CZ (1) CZ195297A3 (en)
DE (1) DE69527805T2 (en)
ES (1) ES2181805T3 (en)
FI (1) FI972683A0 (en)
HU (1) HUT77450A (en)
IL (1) IL116511A0 (en)
MX (1) MX9704575A (en)
NO (1) NO972882L (en)
NZ (1) NZ297529A (en)
PL (1) PL184031B1 (en)
RU (1) RU2189251C2 (en)
SK (1) SK80997A3 (en)
TR (1) TR199501654A2 (en)
WO (1) WO1996020011A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11511970A (en) 1995-08-16 1999-10-19 ゼネカ・リミテッド Chemical compound
TW406454B (en) 1996-10-10 2000-09-21 Berg Tech Inc High density connector and method of manufacture
AU6000698A (en) * 1997-02-14 1998-09-08 Zeneca Limited Proteins
GB9703201D0 (en) * 1997-02-15 1997-04-02 Zeneca Ltd Chemical compounds
GB9709421D0 (en) * 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
JP4616991B2 (en) * 1998-09-18 2011-01-19 イミューノメディクス、インコーポレイテッド Methods and compositions for increasing target specific toxicity of chemotherapeutic agents
US6361774B1 (en) 1999-09-17 2002-03-26 Immunomedics, Inc. Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug
US20040117863A1 (en) * 1998-09-18 2004-06-17 Edge Michael D. Transgenically produced fusion proteins
BR0014527A (en) * 1999-09-17 2002-06-18 Genzyme Transgenics Corp Transgenically produced fusion proteins
WO2004050847A2 (en) * 2002-11-27 2004-06-17 Gtc Biotherapeutics, Inc. Modified antibodies stably produced in milk and methods of producing same
US20080019905A9 (en) * 2005-02-18 2008-01-24 Strome Scott E Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
ES2642787T3 (en) * 2005-10-21 2017-11-20 Lfb Usa, Inc. Antibodies with enhanced antibody dependent cell cytotoxicity activity, methods for their production and use
WO2007149827A2 (en) * 2006-06-20 2007-12-27 Janssen Pharmaceutica, N.V. Method for modulating the pharmacokinetics and metabolism of a therapeutic agent
US20080031866A1 (en) * 2006-06-20 2008-02-07 Eichenbaum Gary M Method for modulating the pharmacokinetics and metabolism of a therapeutic agent
CN101511774B (en) * 2006-10-03 2015-05-13 于崇曦 Positively charged water-soluble prodrugs of mustard gas and related compounds with fast skin penetration rate
GB0709333D0 (en) * 2007-05-15 2007-06-20 Smart Targeting Ltd Binding protein
WO2009134389A2 (en) * 2008-05-01 2009-11-05 Gtc Biotherapeutics, Inc. An anti-cd137 antibody as an agent in the treatment of inflammatory conditions
US10745492B1 (en) 2019-04-03 2020-08-18 Ark Diagnostics, Inc. Antibodies to symmetrically dimethylated arginine analytes and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
US5632990A (en) * 1988-04-22 1997-05-27 Cancer Research Campaign Tech. Ltd. Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
DE69019959T2 (en) * 1989-01-23 1995-10-05 Akzo Nobel Nv LOCAL IN VIVO ACTIVATION OF THERAPEUTIC MEDICINAL PRODUCTS.
US5433955A (en) * 1989-01-23 1995-07-18 Akzo N.V. Site specific in vivo activation of therapeutic drugs
CA2127126A1 (en) * 1992-01-30 1993-08-05 Helen M. Wilks Chiral synthesis with modified enzymes
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
US5389537A (en) * 1994-01-21 1995-02-14 Wisconsin Alumni Research Foundation Nuclease having altered specificity

Also Published As

Publication number Publication date
AU4269796A (en) 1996-07-19
BR9510490B1 (en) 2010-10-05
NO972882L (en) 1997-08-19
TR199501654A2 (en) 1996-07-21
CN1095677C (en) 2002-12-11
JP3805365B2 (en) 2006-08-02
FI972683A (en) 1997-06-19
NZ297529A (en) 1999-07-29
CZ195297A3 (en) 1997-12-17
PL184031B1 (en) 2002-08-30
WO1996020011A1 (en) 1996-07-04
TR199501654A3 (en) 1996-07-21
RU2189251C2 (en) 2002-09-20
CA2205091A1 (en) 1996-07-04
MX9704575A (en) 1997-10-31
DE69527805D1 (en) 2002-09-19
AU701916B2 (en) 1999-02-11
CN1171054A (en) 1998-01-21
KR100270650B1 (en) 2000-11-01
PL320964A1 (en) 1997-11-24
EP0806964B1 (en) 2002-08-14
SK80997A3 (en) 1998-02-04
ATE222124T1 (en) 2002-08-15
HUT77450A (en) 1998-04-28
NO972882D0 (en) 1997-06-20
US5985281A (en) 1999-11-16
FI972683A0 (en) 1997-06-19
IL116511A0 (en) 1996-07-23
ES2181805T3 (en) 2003-03-01
DE69527805T2 (en) 2003-04-24
EP0806964A1 (en) 1997-11-19
JPH10511547A (en) 1998-11-10

Similar Documents

Publication Publication Date Title
BR9510490A (en) Combined two-component system designed for use in a mustard ribonucleotide host pharmaceutical composition half component mutant enzyme process to control neoplastic cell growth in a plasmid host vector and cell polynucleotide sequence
BR0210225A (en) Mutant immunogenic cholera holotoxin, immunogenic composition, method for enhancing a vertebrate host's immune response to an antigen, isolated and purified DNA sequence, nucleic acid molecule, host cell, method for producing a mutant immunogenic cholera holotoxin, and, use of a mutant cholera holotoxin
DK1508620T3 (en) Circular DNA molecule with conditional origin of replication, methods for its preparation and use in gene therapy
DE69636032D1 (en) PLASMIDE FOR THE ADMINISTRATION OF NUCLEIC ACIDS AND METHOD OF USE
BR9812079A (en) Salmonella sp. mutant, lipopolysaccharide, process to inhibit the growth or reduce the volume of a solid tumor cancer, pharmaceutical composition, and, improved process to select genetic alterations in a bacterium.
DE69406423T2 (en) METHOD FOR DELIVERING AGENTS TO TARGET CELLS
PL350658A1 (en) Medical preparations for the treatment of alpha−galactosidase a deficiency
ATE545699T1 (en) MODIFIED RECOMBINANT VACCINIA VIRUSES AND USES THEREOF
BR9808769A (en) Gene construction, use of a gene construct, paired two-component system, designed for use in a mammalian host, and process for transferring a cytotoxic drug to a site
BR9406232A (en) New agent to control cell activity
DE69329735D1 (en) PEPTIDE HYDROCARBON CONJUGATES WHICH T-CELL IMMUNITY
AU3677095A (en) Radioactive phosphorous labeling of proteins for targeted radiotherapy
MY125980A (en) Highly purified cytokine activating factor and methods of use
BR0016129A (en) Nucleic acid molecule, recombinant vector, polypeptide, eukaryotic amino acid racemase, antibodies, host cell, methods to produce polypeptide, to detect a parasite and a eukaryotic protein, to screen active molecules, to detect and quantify the presence or absence of a sequence, to inhibit a eukaryotic protein, to produce a eukaryotic and d-aminoacid recombinant amino acid racemase and to prevent or inhibit infection, plasmid, immune complex, kit to detect a parasite, fragment of a polynucleotide, eukaryotic protein, processes to prepare a purified eukaryotic protein, to detect an infection and for infection and to screen a molecule, immunizing composition, vaccine composition, any molecular modification of the gene or a fragment of the gene, use of any molecular or biochemical modification of the enzymatic activity of the racemase, and , any molecule or composition to
BR9610050A (en) Conjugate, combined two-component systems intended for use in a host, compounds or a pharmaceutically acceptable salt thereof, enzyme, polynucleotide and de02 nucleotide sequence, vector, host cell, enzyme and conjugate production processes and treatment of neoplastic cells in a host, pharmaceutical composition and plasmid
TR200101141T2 (en) Pharmaceutical composition containing fragments of a DNA encoding antigenic protein with antitumor effect
BR9709700A (en) Viral vector cell pharmaceutical composition process of preparing in situ replicative circular DNA molecules using a viral vector process for the transfer of nucleic acids to a replicating circular DNA molecule
TR200002611T2 (en) Beta-lipotropin and its uses
WO2022172083A3 (en) Targeted nucleic acid therapy for hepatitis b
Okamoto et al. In vitro expression of plasmid pUB110 DNA with Bacillus subtilis cell-free extracts
JO1766B1 (en) New active compounds
GB2309033A (en) Chemical compounds
TW332816B (en) Peptide and carbohydrate

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: COM BASE NO ARTIGO 8O DA LPI DE 9279/96 COMBINADO COM O ARTIGO 13 DA LPI DE 9279/96, DECIDIMOS PELO INDEFERIMENTO DO PRESENTE PEDIDO.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B25D Requested change of name of applicant approved

Owner name: SYNGENTA LIMITED (GB)

Free format text: ALTERADO DE: ZENECA LIMITED

B25G Requested change of headquarter approved

Owner name: SYNGENTA LIMITED (GB)

Free format text: ANOTADAS AS ALTERACOES DE SEDE, CONFORME SOLICITADO NA PETICAO NO 020070050229/RJ DE 19/04/2007.

B25A Requested transfer of rights approved

Owner name: ASTRAZENECA UK LIMITED (GB)

Free format text: TRANSFERIDO DE: SYNGENTA LIMITED

B25A Requested transfer of rights approved

Owner name: LONDON BIOTECHNOLOGY LIMITED (GB)

Free format text: TRANSFERIDO DE: ASTRAZENECA UK LIMITED

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 05/10/2010, OBSERVADAS AS CONDICOES LEGAIS.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI-52400.061577/2013 ORIGEM: JUIZO DA 013A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0132353-78.2013.4.02.5101 ACAO DE NULIDADE DAS PATENTES SUBMETIDAS AO MAILBOX (ART. 229, PARAGRAFO UNICO DA LPI); ALTERNATIVAMENTE, A DECRETACAO DA NULIDADE PARCIAL PARA CORRECAO DO PRAZO DE VIGENCIA; SUBSIDIARIAMENTE, CASO SE ENTENDA NAO SER O CASO DE NULIDADE, A CORRECAO DO ATO ADMINISTRATIVO PARA ADEQUACAO DA VIGENCIA DAS PATENTES. AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU: KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO, LONDON BIOTECHNOLOGY LIMITED, MERCK SHARP AND DOHME, N.V. ORGANON, NICOX S.A.

B24C Patent annual fee: request for for restoration

Free format text: REFERENTE A 18A ANUIDADE.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time
B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: MANUTENCAO DA EXTINCAO - ART. 78 INCISO IV DA LPI

B15K Others concerning applications: alteration of classification

Ipc: B82Y 5/00 (2011.01), A61K 47/68 (2017.0

B19A Notification of judicial decision: notification of judicial decision

Free format text: INPI-52400.061577/2013-10 SECAO JUDICIARIA DO RIO DE JANEIRO 9A VARA FEDERAL DO RIO DE JANEIRO PROCESSO: NO0132353-78.2013.4.02.5101APELANTE: MERCK SHARP AND DOHME CORP E OUTROS APELADO: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL ? INPI DECISAO: A CONTROVERSIA SOBRE O PRAZO DE VIGENCIA DAS PATENTES MAILBOX FOI DEVIDAMENTE APRECIADA POR ESTE TRIBUNAL NO AMBITO DAS TURMAS ESPECIALIZADAS, ASSIM COMO TAMBEM NO DA SECAO, ALEM DO E. STJ, TENDO SIDO CONSOLIDADO O ENTENDIMENTO NO SENTIDO DE QUE O PARAGRAFO UNICO DO ARTIGO 40 DA LEI NO9.279/96 NAO SE APLICA AS PATENTES ?MAILBOX?, DIANTE DA LIMITACAO ESTABELECIDA PELO ARTIGO 229, PARAGRAFO UNICO, DA MESMA LEI DEVENDO SER APLICADO O PRAZO DE VIGE